Autologous stem cell transplant in ALL: who should we be transplanting in first remission? (Q36457738)

14 August 2017

1 reference

title

Autologous stem cell transplant in ALL: who should we be transplanting in first remission? (English)

1 reference

14 August 2017

2

Luger SM

1 reference

14 August 2017

Mato AR

1

1 reference

PubMed ID

16633362

14 August 2017

language of work or name

English

0 references

publication date

1 June 2006

1 reference

Bone Marrow Transplantation

14 August 2017

1 reference

14 August 2017

37

1 reference

14 August 2017

11

1 reference

14 August 2017

989-995

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.bmt.1705370

14 August 2017

0 references

cites work

The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute lymphoblastic leukemia in children: an evidence-based review

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705370

The use of a sequential high dose recombinant interleukin 2 regimen after autologous bone marrow transplantation does not improve the disease free survival of patients with acute leukemia transplanted in first complete remission

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705370

Long-term results of autologous bone marrow transplantation in adult acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705370

Better outcome of adult acute lymphoblastic leukemia after early genoidentical allogeneic bone marrow transplantation (BMT) than after late high-dose therapy and autologous BMT: a GOELAMS trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705370

Autologous stem cell transplantation in acute lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705370

The role of posttransplantation maintenance chemotherapy in improving the outcome of autotransplantation in adult acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705370

Autologous Bone Marrow Transplantation in Adult Patients with Acute Lymphoblastic Leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705370

Allograft and autograft purging using immunotoxins in clinical bone marrow transplantation for hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705370

Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer--Childhood Leukemia Cooperative Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705370

Identification of novel markers for monitoring minimal residual disease in acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705370

Accurate quantitation of residual tumor burden at bone marrow harvest predicts timing of subsequent relapse in patients with common ALL treated by autologous bone marrow transplantation. Nagoya BMT Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705370

Outcome of treatment in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia--results of the prospective multicenter LALA-94 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705370

Early prediction of response in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) treated with imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705370

Adult acute lymphocytic leukemia study testing chemotherapy and autologous and allogeneic transplantation. A follow-up report of the French protocol LALA 87.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705370

An anti-CD19 antibody inhibits the interaction between P-glycoprotein (P-gp) and CD19, causes P-gp to translocate out of lipid rafts, and chemosensitizes a multidrug-resistant (MDR) lymphoma cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705370

High-dose melphalan and autotransplantation followed by post transplant maintenance chemotherapy for acute lymphoblastic leukemia in first remission

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705370

Treatment of terminal leukemic relapse by total-body irradiation and intravenous infusion of stored autologous bone marrow obtained during remission

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705370

7 January 2021

Adult acute lymphoblastic leukemia: a multicentric randomized trial testing bone marrow transplantation as postremission therapy. The French Group on Therapy for Adult Acute Lymphoblastic Leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705370

7 January 2021

Outcome of treatment in adults with acute lymphoblastic leukemia: analysis of the LALA-94 trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705370

7 January 2021

Adult acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705370

7 January 2021

Induction-consolidation with an idarubicin-containing regimen, unpurged marrow autograft, and post-graft chemotherapy in adult acute lymphoblastic leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705370

7 January 2021

Autologous and allogeneic stem cell transplantation in adult ALL: the Swedish Adult ALL Group experience

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705370

7 January 2021

The dismal outcome in patients with acute leukaemia who relapse after an autograft is improved if a second autograft or a matched allograft is performed. Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT)

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705370

7 January 2021

Primary refractory and relapsed adult acute lymphoblastic leukemia: characteristics, treatment results, and prognosis with salvage therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705370

7 January 2021

Identifiers

DOI

10.1038/SJ.BMT.1705370

1 reference

14 August 2017

1 reference

PubMed ID

16633362